Efficacy of epoetin-beta 30,000 IU/week in correcting anaemia in patients with gastrointestinal tumours subjected to concomitant chemoradiotherapy.

• Autores: Antonio Gómez Caamaño, Mercedes Salgado Fernández, Manuel Valladares Ayerbes, Mónica Jorge Fernández, Ana Carballo Castro, Sonia Candamio Folgar, Pilar Izquierdo, Paula Peleteiro Higuero, Rafael López López
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 12, Nº. 12, 2010, págs. 843-848
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective The aim of the project was to assess the effectiveness and safety of weekly epoetin-beta (EB) in patients with gastrointestinal cancer (GIC) subjected to concomitant chemoradiotherapy (CCTRT).

    Methods In this clinical prospective and multicentre cohort study EB was administered at a dose of 30,000 IU/ week, during CCTRT and in the four weeks thereafter, and suspended if haemoglobin (Hb) increased >2 g/dl or Hb >12�13 g/dl. Effectiveness was defined as Hb increase ?1 g/dl vs. baseline. Time to response, treatment toxicity and transfusion requirements were also assessed.

    Results EB was effective in 75.8% of the evaluable population within a median of four weeks from EB initiation, without blood transfusions. Over 80% of all patients remained below the threshold (Hb ?13 g/dl) and no study drug-related adverse reactions were recorded.

    Conclusion Weekly EB proved to be effective and well tolerated by patients with GIC subjected to CCTRT